Abstract: The present invention relates to compounds exhibiting central nervous system (CNS) activity which are useful in the treatment of epilepsy and other CNS disorders. The compounds of this invention have the following general formula: ##STR1## and pharmaceutically acceptable salts thereof.
Abstract: Aqueous stable injectable formulations containing the sodium salt of naproxen, stabilizing agents and polyhydroxylic alcohols, packaged in containers made up of boxes of polystyrene or of an equivalent material covered with films which absorb the light radiations.
Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs 13-(substituted mercapto) derivatives of tetracycline in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously or concurrently. The concomittantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state. The combination also effects a synergistic bacteriocidal activity against susceptible and resistant cells.
Abstract: A synergistic fungicidal composition comprising a fungicidally effective amount of (I) a 1,2,4-triazolylalkonol of the formula ##STR1## in which X is chlorine or phenyl plus (II) at least one member selected from the group consisting of(A) a salt of a heavy metal,(B) a guanidine or derivative, and(C) a polyhalogenoalkylthio derivative of the formula ##STR2## in which R.sup.1 is amidosulphonyl or dimethylamidosulphonyl,R.sup.2 is phenyl, methylphenyl or halogeno phenyl, orR.sup.1 and R.sup.2 together are ##STR3## Haloalkyl is alkyl which has up to 2 carbon atoms and is substituted by 2 to 5 halogen atoms.
October 18, 1989
Date of Patent:
October 22, 1991
Wilhelm Brandes, Helmut Kaspers, Paul Reinecke, Hans Scheinpflug, Wolfgang Kramer
Abstract: A one phase, liquid composition for oral administration comprises a NSAID such as an anthranilic acid derivative plus a di- or triglyceride of a medium chain fatty acid edible oil which has the characteristics of a pharmaceutical solvent carrier as known to those skilled in the art. Other pharmaceutical additives may be optionally added. An additional stipulation is that ethanol or other monohydric alcohol solvents should not be present.
Abstract: A method of reducing the negative effects of heavy metals and a method of preventing or alleviating immunodeficiency, hypertension and dermatitis in mammals is disclosed. In these methods pharmaceutical compositions are administered to a mammal in need thereof. The particular pharmaceutical composition includes a reducing, preventing or alleviating effective amount, for the particular condition, of at least one isomer of inositol triphosphate.
Abstract: A fluorine-containing vitamin D.sub.2 derivative represented by the following formula ##STR1## wherein R.sup.1 represents a methyl or trifluoromethyl group, and R.sup.2 represents a trifluoromethyl group when R.sup.1 is a methyl group, and a hydrogen atom or a methyl group when R.sup.1 is a trifluoromethyl group. This compound is useful for the prevention or treatment of calcium pathobolism or osteoporosis.
Abstract: A method of treatment of depressive states which comprises administering in mammals in need thereof an effective amount of a compound ##STR1## R.sub.1 represents hydrogen, a halogen atom, a cyano group a nitro group, an acetyl group or a trifluoromethyl group;R.sub.2 represents a hydroxyl group, in which case R.sub.3 represents a hydrogen atom, or R.sub.2 and R.sub.3 taken together represent an additional bond between the carbon atoms by which they are carried; andR.sub.4 represents a 2-oxopyrrolidin-1-yl or 2-oxopiperid-1-yl group or a heterocyclic group selected from 1H-pyrid-2-on-1-yl, 1H-pyridazin-6-on-1-yl, 1H-pyrimidin-2-on-1-yl, 1H-pyrimidin-6-on-1-yl, 1H-pyrazin-2-on-1-yl and 1H-thiopyrid-2-on-1-yl groups which are unsubstituted or monosubstituted or disubstituted by a C.sub.1 -C.sub.4 alkyl group, a halogen atom or a hydroxyl, nitro, amino or carboxyl group and the pharmaceutically acceptable salts thereof.
Abstract: A method of treating diabetes or complications of diabetes is disclosed. In this method a pharmaceutically effective amount of at least one isomer of inositol triphosphate is administered to a human or an animal in need thereof.
Abstract: A pharmaceutical composition which comprises a mixture of an alpha-2 adrenoceptor antagonist, preferably idazoxan, or a pharmaceutically acceptable salt thereof, and either a catecholamine precursor or carbidopa.
April 28, 1989
Date of Patent:
May 14, 1991
National Research Development Corporation
Abstract: Drug treatment therapies and kits for use therewith are disclosed. They involve the use of methimazole and/or its pro-drug carbimazole to reduce nephrotoxic effects of chemical exposure. In one embodiment, a patient receives cisplatin and then is treated with methimazole. The time delay in providing methimazole prevents the methimazole from being substantially expelled by the kidney prior to cisplatin reaching the kidney.
Abstract: This invention relates to the use of tenidap, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-1-carboxamide, and the pharmaceutically-acceptable base salts thereof to inhibit the release of elastase by neutrophils in a mammal. This invention also relates to the use of tenidap and its salts for treating elastase-mediated diseases and dysfunctions such as arteritis, proteinuria and pulmonary emphysema in mammals. The methods of this invention comprise administering an effective amount of tenidap or salts thereof to a mammal.